Table 2.
Demographics and characteristics of patients after propensity score matching.
| Variables | Green tea (n = 425) | Non-green tea (n = 425) | p-value |
|---|---|---|---|
| Age-years | 71.2 ± 22.5 | 68.4 ± 18.1 | 0.512 |
| Sex (female/male)-no. (%) | 204 (48.0)/221(52.0) | 218 (51.3)/207(48.7) | 0.337 |
| BMI-kg/m2 | 22.7 ± 5.1 | 21.4 ± 4.6 | 0.459 |
| Previous VTE (Y/N)-no. (%) | 45(10.6)/380(89.4) | 42(9.9)/383(90.1) | 0.734 |
| Hypercoagulability (Y/N)—no. (%) | 80(18.8)/345(81.2) | 85(20.0)/340(80.0) | 0.665 |
| Medical comorbidities (Y/N)—no. (%) | 235(55.3)/190(44.7) | 228(53.6)/197(46.4) | 0.630 |
| Primary site of cancer-no. (%) | |||
| Prostate Breast Lung Lymphoma Gynecologic Bladder Brain Stomach Pancreas Others |
49(11.5) 52(12.2) 55(12.9) 44(10.4) 51(12.0) 22(5.2) 18(4.2) 50(11.8) 37(8.7) 47(11.1) |
47(11.1) 54(12.7) 52(12.2) 43(10.1) 56(13.2) 20(4.7) 15(3.5) 48(11.3) 40(9.4) 50(11.8) |
0.828 0.836 0.756 0.910 0.605 0.752 0.594 0.830 0.720 0.746 |
| Performance status-points | 2.1 ± 1.5 | 1.9 ± 1.3 | 0.549 |
| Metastasis (Y/N)—no. (%) | 222(52.2)/203(47.8) | 208(48.9)/217(51.1) | 0.337 |
| VTE-related anticancer therapies-no. (%) | |||
| Major surgery Chemotherapy Immunotherapy Protein kinase inhibitor Hormonal therapies Antiangiogenic therapies |
140(32.9) 301(70.8) 88(20.7) 171(40.2) 60(14.1) 77(18.1) |
144(33.9) 295(69.4) 85(20.0) 167(39.3) 65(15.3) 72(16.9) |
0.771 0.653 0.798 0.779 0.628 0.652 |
| CVC (Y/N)—no. (%) | 198(46.6)/227(53.4) | 193(45.4)/232(54.6) | 0.731 |
| Hospitalization or prolonged immobilization (Y/N)—no. (%) | 308(72.5)/117(27.5) | 303(71.3)/122(28.7) | 0.703 |
| Use of red cell growth factors (Y/N)—no. (%) | 146(34.4)/279(65.6) | 140(32.9)/285(67.1) | 0.663 |
| Hemoglobin-g/L | 125.3 ± 37.1 | 121.8 ± 33.6 | 0.906 |
| Platelet- × 109/L | 218.9 ± 96.1 | 206.4 ± 107.8 | 0.212 |
| Leukocyte- × 109/L | 7.7 ± 4.4 | 7.2 ± 4.8 | 0.972 |
| D-dimer-mg/L | 1.6 ± 1.4 | 1.4 ± 1.2 | 0.162 |
| Khorana score-points | 1.8 ± 1.7 | 1.9 ± 1.5 | 0.708 |
| Thromboprophylaxis-no. (%) | |||
| Overall LMWH DOAC Warfarin |
372(87.5) 310(72.9) 44(10.4) 18(4.2) |
366(86.1) 304(71.5) 47(11.1) 15(3.5) |
0.543 0.646 0.739 0.594 |
no., number; BMI, body mass index; kg/m2, kilogram/meter2; Y/N, yes/no; VTE, venous thromboembolism; CVC, central venous catheterization; L, liter; g/L, gram/liter; mg/L, milligram/liter; LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant. Medical comorbidities denote infection, renal disease, pulmonary disease, congestive heart failure, or arterial thromboembolism at the diagnosis of cancer. Since the same patient may receive multiple anticancer therapies, the sum of the various VTE-related anticancer therapies may be greater than 100%. The variables at the diagnosis of cancer were adopted for age, BMI, PS, metastasis, hemoglobin, platelet, leukocyte, D-dimer, and Khorana score.